BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Phase 2

Completed

Conditions: Active Psoriatic Arthritis

Interventions: Other: BMS-986165 Placebo
Drug: BMS-986165 Dose A
Drug: BMS-986165 Dose B
Other: Ustekinumab Placebo
Drug: Ustekinumab

First Posted Date: 2019-03-19

Last Posted Date: 2022-02-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 203

Registration Number: NCT03881059

Locations: 🇺🇸
San Marcus Research Clinic, Miami Lakes, Florida, United States
🇺🇸
Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸
Arthritis Associates, Hattiesburg, Mississippi, United States

and more 91 locations

Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy Males

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165

First Posted Date: 2019-03-13

Last Posted Date: 2019-11-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03873415

Locations: 🇺🇸
Scintipharma, Lexington, Kentucky, United States

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Phase 3

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Other: Ipilimumab placebo
Biological: Ipilimumab

First Posted Date: 2019-03-13

Last Posted Date: 2024-01-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 437

Registration Number: NCT03873402

Locations: 🇪🇸
Local Institution - 0038, Barcelona, Spain
🇷🇴
Local Institution - 0065, Craiova, Romania
🇺🇸
Local Institution - 0013, Washington, District of Columbia, United States

and more 75 locations

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Phase 1

Completed

Conditions: Malignant Solid Tumor

Interventions: Drug: AVID200

First Posted Date: 2019-02-08

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 19

Registration Number: NCT03834662

Locations: 🇺🇸
START Midwest Clinic, Grand Rapids, Michigan, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇦
Princess Margaret Cancer Centre, Toronto, Canada

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

Phase 1

Completed

Conditions: Scleroderma, Diffuse

Interventions: Drug: AVID200

First Posted Date: 2019-02-05

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT03831438

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Hospital of Special Surgery, New York, New York, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 1 locations

A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Other: Non-Interventional

First Posted Date: 2019-01-15

Last Posted Date: 2022-05-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 503

Registration Number: NCT03804554

Locations: 🇦🇺
Local Institution, Heidelburg, Victoria, Australia

A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: BMS-986205
Biological: Nivolumab

First Posted Date: 2019-01-03

Last Posted Date: 2022-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT03792750

Locations: 🇨🇳
Local Institution, Hangzhou, Zhejiang, China

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Active, not recruiting

Conditions: Melanoma

First Posted Date: 2018-12-11

Last Posted Date: 2021-09-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 152

Registration Number: NCT03771859

Locations: 🇱🇺
Local Institution, Luxembourg, Luxembourg

An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

Phase 2

Withdrawn

Conditions: Circulating Tumor DNA
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma

Interventions: Biological: Nivolumab
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Docetaxel
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Other: Observation

First Posted Date: 2018-12-10

Last Posted Date: 2022-03-24

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03770299

A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Other: Non-Interventional

First Posted Date: 2018-12-07

Last Posted Date: 2020-03-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 264

Registration Number: NCT03769558

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy